Tag: G1 Therapeutics

December 20, 2018

G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind,...
November 27, 2018

G1 Therapeutics Releases Phase 2 Data

Trilaciclib was tested in combination with chemotherapy and the checkpoint inhibitor Tecentriq in first-line small cell lung cancer patients.
November 27, 2018

G1 Therapeutics Announces Positive Myelopreservation Data

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating...
October 22, 2018

8 Top Gains and Losses at 2018’s ESMO Event

Big Pharma players and smaller oncology-focused companies alike were among the presenters at the annual meeting, which runs from October...
April 16, 2018

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38,...
March 8, 2018

G1 Therapeutics Announces Pricing of Offering of Common Stock

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of...
March 5, 2018

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data from its Phase 2a trial evaluating trilaciclib in...